Loading...
Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report
Chimeric antigen receptor (CAR)-modified T-cells targeting CD19 represent a promising therapy for relapsed or refractory (r/r) lymphoma and leukemia. The most common adverse events are immune related and include cytokine release syndrome and neurotoxicity. However, early and late hematological toxic...
Na minha lista:
| Udgivet i: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8287610/ https://ncbi.nlm.nih.gov/pubmed/34272307 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002721 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|